Login to Your Account



Gene Signal Raises New Cash for Its Antisense Drug Trials

By Cormac Sheridan
Staff Writer

Wednesday, January 30, 2013
With data due from a pivotal Phase III trial of its lead drug candidate around midyear, Gene Signal International SA raised an undisclosed investment from its longstanding syndicate of private investors to keep its pipeline of antisense and peptide-based drugs moving forward.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription